Skip To Main Content
Pamela N Munster on Muck Rack

Pamela N Munster

As seen in: Nature, TIME, The Wall Street Journal, JAMA Oncology, Salon, Science Magazine, Healio, Scary Mommy, HAL, Journal of Clinical Oncology and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Pamela N

Contact Pamela N, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Cracks in the Estrogen Carcinogenesis of Breast Cancer

|
By Pamela N Munster
| Journal of Clinical Oncology Verified
3 Earlier epidemiologic studies reported an increase in breast cancer risk among postmenopausal women taking either estrogen-only HRT or estrogen-progestin HRT (to a larger degree).3 Multiple randomized clinical trials (RCTs), as well as recent cohort studies, affirm that estrogen-progestin HRT raises breast cancer risk.9-11 Unexpectedly, these studies also noted that women on estrogen-only HRT exhibit a lower risk of breast cancer than nonusers or placebo controls.9-12 Notably, the Women's...
Open in Who Shared Issue with article?

Characterizing safety, toxicity, and breast cancer risk reduction using a long-term fulvestrant eluting implant - Scientific Reports

|
By Pamela N Munster
| Nature Verified
Abstract For individuals at high risk of developing breast cancer, interventions to mitigate this risk include surgical removal of their breasts and ovaries or five years treatment with the anti-estrogen tamoxifen or aromatase inhibitors. We hypothesized that a silicone based anti-estrogen-eluting implant placed within the breast would provide the risk reduction benefit of hormonal therapy, but without the adverse effects that limit compliance.
Open in Who Shared Issue with article?

22 Updated Results From VERITAC Evaluating Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer

|
By Sara A. Hurvitz, Anne F. Schott, Cynthia X. MA, Rita Nanda, George Zahrah, Natasha Hunter, Antoinette R. Tan, Melinda L. Telli, Jesus Anampa Mesias, Rinath Jeselsohn, Pamela N Munster, Eric Zhi, Elizabeth K Duperret, Cecile Mather, Erika Hamilton, Hyo S Han
| ONCOLOGY journal Verified
Background Vepdegestrant (ARV-471) is an oral proteolysis-targeting chimeric (PROTAC) estrogen receptor (ER) degrader with activity toward wild-type and mutant ER. The phase 2 expansion (VERITAC) of a phase 1/2 study tested 2 vepdegestrant doses (200 mg once daily and 500 mg once daily) in heavily pretreated patients with ER+/HER2-negative (HER2–) advanced breast cancer.
Open in Who Shared Issue with article?
See all 16 licensed articles (17 Total)